MIAMI, FLORIDA (OCT. 20, 2025) – A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with ...

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

Novel regimen GO-4, combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells shows manageable adverse reactions and a strong signal of efficacy in patients with BRCA-relat ...

New gene-editing project targets thalassemia’s root cause A new research project at the Cyprus Institute of Neurology and ...

When Adele Miner was five, and her mother seven months pregnant, she discovered her father was having an affair. Here she ...

From the 2010s to the present, the existing technologies in the clinic and operating room have been improved with the goals ...

The new luxury for the ultra-high-net-worth individual is not a product but time, driving a trillion-dollar global wellness ...

New research found that gene therapy for children with a form of severe combined immunodeficiency was successful in 95% of ...

Touted by longevity experts, celebrated by biohackers, and whispered about in elite wellness circles, NAD+ is the molecule at ...

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.